PRESS RELEASE : Apogenix AG: COVID-19 targeted treatment trial launched in Vienna marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
DGAP-News: Apogenix AG / Key word(s): Study
22.12.2020 / 10:00
COVID-19: targeted treatment trial launched in Vienna
(Vienna/Heidelberg/Cologne/London, 22 December 2020) A phase II clinical trial of a treatment for COVID-19 patients is currently starting at the Medical University of Vienna as a sub-study of the Austrian CoronaVirus Adaptive Clinical Trial (ACOVACT). The trial was initiated as an academia-industry collaboration (investigator Initiated trial) between Apogenix AG, a biotech company based in Heidelberg, and their scientific consultant Henning Walczak and his teams at the University of Cologne and University College London (UCL).
Patients with severe to critical COVID-19 are now being treated with an immunotherapeutic drug, the Fas ligand blocker asunercept, from Apogenix within the framework of the Austrian CoronaVirus Adaptive Clinical Trial (ACOVACT). ACOVACT is a randomised, controlled, multi-centre, open-label clinical trial sponsored by MedUni Vienna. Within
E-Mail
Lower rates of hospital attendance for urgent heart problems during the initial phase of the COVID-19 pandemic may have contributed to avoidable deaths in England, finds a new study led by UCL researchers.
In the wake of the coronavirus pandemic, a marked decline in patient visits to Emergency Departments (EDs) was observed in England and the US, including for people with heart problems.
In this study, published online in the journal
Circulation cardiovascular quality and outcomes, researchers at UCL s Institute of Health Informatics estimated the effect of reduced ED visits for suspected cardiac disease on non-COVID-19 related cardiac mortality in England.
No association between COVID-19 and Guillain-Barré syndrome
Neuroscientists at UCL have found no significant association between COVID-19 and the potentially paralysing and sometimes fatal neurological condition Guillain-Barré syndrome.
Researchers say the findings, published in the journal Brain , along with a linked scientific commentary by UCL and other international experts, should provide the public with reassurance, as the UK s national coronavirus vaccination programme is rolled out.
Guillain-Barré syndrome (GBS) is a rare but serious autoimmune condition that attacks the peripheral nervous system, typically affecting the feet, hands and limbs, causing numbness, weakness and pain. While its exact cause is unknown, GBS often occurs after a gastroenteritis infection called Camplylobacter, with the immune system mistakenly attacking nerves rather than germs.